Paradigm Capital Management LLC NV Sells 590 Shares of Johnson & Johnson $JNJ

Paradigm Capital Management LLC NV lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 5.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,965 shares of the company’s stock after selling 590 shares during the period. Johnson & Johnson comprises about 1.7% of Paradigm Capital Management LLC NV’s portfolio, making the stock its 18th largest holding. Paradigm Capital Management LLC NV’s holdings in Johnson & Johnson were worth $1,653,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Highline Wealth Partners LLC grew its position in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the 1st quarter valued at about $47,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the 1st quarter valued at about $49,000. Capital A Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at about $50,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $176.26 on Tuesday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a market capitalization of $424.49 billion, a P/E ratio of 18.85, a P/E/G ratio of 2.25 and a beta of 0.41. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $177.57. The firm has a 50-day moving average price of $161.70 and a two-hundred day moving average price of $158.60.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.82 EPS. Analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson’s payout ratio is currently 55.61%.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Leerink Partnrs downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Wall Street Zen downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 18th. Guggenheim reissued a “neutral” rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Bank of America lifted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Thursday, July 17th. Finally, Morgan Stanley lifted their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.